Yağcı, A. M. 2022. Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty. asco , (Illinois, United States Of America), 448.

Yağcı, A. M., (2022). Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty . asco (pp.448). Illinois, United States Of America

Yağcı, ABDULLAH. "Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty," asco, Illinois, United States Of America, 2022

Yağcı, ABDULLAH M. . "Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty." asco , Illinois, United States Of America, pp.448, 2022

Yağcı, A. M. (2022) . "Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty." asco , Illinois, United States Of America, p.448.

@conferencepaper{conferencepaper, author={ABDULLAH MÜNCİ YAĞCI}, title={Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty}, congress name={asco}, city={Illinois}, country={United States Of America}, year={2022}, pages={448} }